JP Morgan Chase
CADX

JP Morgan Chase’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

JP Morgan Chase’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-29,713
Closed -$269K – 4200
2013
Q4 		$269K Buy
29,713
+9,312
+46% +$67.2K ﹤0.01% 3726
2013
Q3 		$129K Sell
20,401
-3,970
-16% -$25.2K ﹤0.01% 4137
2013
Q2 		$167K Buy
+24,371
New +$170K ﹤0.01% 4037

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase's CADX Position: Q1 2014 in Review

JP Morgan Chase sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 29,713 shares — an estimated $269K sold.

JP Morgan Chase first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $269K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • JP Morgan Chase reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • JP Morgan Chase sold 29,713 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $269K.
  • JP Morgan Chase first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • JP Morgan Chase's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $269K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on JP Morgan Chase's 13F filing for Q1 2014, filed 15 May 2014.